News

Mobile Intelligence features superior 360° view of customer interactions, intuitive Graphical User Interface (GUI) that drives high end user adoption. In addition, it comprises modules for account objectives

The primary endpoints of the human trial for GLPG0974 will be to determine the pharmacokinetics and to evaluate biomarker effects of this candidate drug. The placebo-controlled, double-blind, single

The primary objectives of the multi-centre, single-blind study are to compare the relative efficacy of the two anti-TNF therapies during short- and long-term treatment (12 and 104 weeks

The Quad contains four Gilead compounds in a complete once-daily, single-tablet regimen which includes elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. The MAA for the Quad is supported

As per the agreement, Hua will receive the full preclinical and clinical documentation for Roche’s GKA program, drug product API for RO5305552, and rights to potential back-up compounds.

Both the companies collaborate on ProteoTech’s small molecule technology platform against misfolded proteins to work on its alpha-synuclein therapeutic program. Michael J. Fox Foundation for Parkinson’s Research has

The new patent is estimated to provide protection until March 2027. Marshall CEO and president Daniel Gold said the patent represents another important milestone in their efforts to

Pfizer is responsible for the clinical development, manufacturing, and commercialization of the product in the licensed territory, as well as certain non-exclusive territories outside of North America. As

Edarbyclor is a once-daily fixed-dose combination regimen of azilsartan medoxomil and diuretic chlorthalidone. The recommended starting dose of Edarbyclor is 40/12.5 mg and the maximum dose is 40/25